Clinical Trials
511
Active:12
Completed:91
Trial Phases
6 Phases
Early Phase 1:8
Phase 1:17
Phase 2:54
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (314 trials with phase data)• Click on a phase to view related trials
Not Applicable
177 (56.4%)Phase 2
54 (17.2%)Phase 4
41 (13.1%)Phase 1
17 (5.4%)Phase 3
17 (5.4%)Early Phase 1
8 (2.5%)Independent Effects of Visceral Adipose Volume and Density on Patient Survival in Peritoneal Dialysis
Completed
- Conditions
- UremiaEnd Stage Renal Disease on Dialysis
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 358
- Registration Number
- NCT07086430
Etomidate Combined With Propofol Versus Propofol for Sedation in High-Altitude Patients During Gastroscopy: a Randomized Multicenter Clinical Trial
Not Applicable
Not yet recruiting
- Conditions
- Gastrointestinal Endoscopy
- Interventions
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 732
- Registration Number
- NCT07079176
REST4-AAA Registry
Not yet recruiting
- Conditions
- Abdominal Aortic Aneurysm
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT07056491
- Locations
- 🇨🇳
Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
The Effectiveness of a TTM-based Multidisciplinary Collaboration on Cardiac Rehabilitation Outcomes in Patients With AMI
Not Applicable
Completed
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT07045220
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
🇨🇳Renji Hospital, Shanghai, China
HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
Not yet recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT07045558
- Locations
- 🇨🇳
Renji Hospital affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 102
- Next
News
Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer
Phase 2 study demonstrates remarkable 93.3% objective response rate for lenvatinib plus tislelizumab in treating fumarate hydratase-deficient renal cell carcinoma, with 20% achieving complete response.